Modafinil and its counterpart Armodafinil are key players in treating ADHD and other daytime sleepiness disorders, yet their high costs can be a barrier for many. While some users claim a noticeable difference between brand name and generic versions, research lacks concrete evidence to support these beliefs. The conversation delves into the nuances of drug effectiveness and the intriguing impact of perception on treatment outcomes.
